Benzodiazepines are one of the classes of compounds which bind at the
benzodiazepine site in the central nervous system. The benzodiazepine
site is phylogenetically new and modulates allosterically the GABA-chl
oride ionophore. This complex is a pentamer surrounding the chloride c
hannel and is made up of various combinations of alpha, beta and gamma
subunits. The anatomical distribution of these subunits is diverse an
d underlies the differential binding of a number of benzodiazepine mod
ulators in the brain. Other compounds which act at this complex includ
e bicuculline, musicmol, ethanol and neurosteroids. Modulation at the
benzodiazepine site is bidirectional. The net result of positive modul
ation is facilitation of conductance and thus hyperpolarisation i.e. a
n inhibitory effect, while negative modulation has the inverse effects
. There is considerable receptor reserve at this complex, in addition
since modulators depend on the presence of GABA for their effects, sup
raphysiological stimulation does not occur. These factors account for
the extreme safety of benzodiazepines and explain the lack of selectiv
ity of action of full agonists, since small increases in fractional oc
cupancy are enough to produce the full gamut of effects. The same howe
ver does not apply to partial agonists which manifest the different ac
tions at well separated receptor occupation. Endogenous ligands have n
ot yet been found for these sites, although benzodiazepines have been
found in brains collected prior to their pharmaceutic marketing-these
probably originate from vegetable foodstuffs and gut bacteria. Changes
in this site can be induced by stress, convulsions and repeated admin
istration of modulators and animals bred for different sensitivity at
the benzodiazepine site manifest consistent behavioural differences. T
hese observations have instigated a search for potential endogenous in
verse agonists in human anxiety disorders and epilepsy and for endogen
ous agonists in metabolic encephalopathies. While thus far this has no
t been successful the putative isolation of endozapines in the rare co
ndition of idiopathic recurrent stupor indicate that this may be a use
ful line of research. In addition the emergence of partial agonists at
these sites which have fewer side effects is likely to rekindle inter
est in the clinical use of such compounds in a variety of neurological
and psychiatric syndromes.